ERS Course
Lung transplantation:
Sharing experience across Europe
19-21 November 2020
Budapest, Hungary

Thursday, 19 November 2020

08:30–08:45  Registration and welcome from the organisers
08:45–09:00  Welcome and identification of participants’ learning needs – G. Massard

Session 1 – Introduction
Chair: G. Massard
09:00–09:20  History of lung transplantation – I. Inci
09:20–10:00  The key elements of a lung transplant programme - J. Gottlieb
10:00–10:25  Coffee Break

Session 2 – Identifying and managing lung transplant candidates
Chair: G. Verleden
10:25–10:50  Referral guidelines and specific criteria for candidate selection in CF, ILD, COPD and PH – G. Verleden
10:50–11:15  Candidate selection and management: specific controversial and ethical issues – R. Vos
11:15–11:40  Paediatric candidates: special issues – TBD
11:40–12:05  Mechanical ventilation and extracorporeal support prior to lung transplantation – A. Neyrinck
12:05–13:00  Lunch

Session 3 – Donor organ availability
Chairs: G. Massard
13:00–13:30  Pushing the boundaries of usable donors: marginal donors – I. Inci
13:30–14:00  Non heart-beating donors – A. Neyrinck
14:00–14:30  Ex-vivo donor lung perfusion – D. van Raemdonck
14:30–15:00  Size reduction and living lobar transplantation – G. Massard
15:00–15:20  Coffee Break
Interactive workshops 1: Case examples and discussion

<table>
<thead>
<tr>
<th>Time</th>
<th>Basic programme</th>
<th>Advanced programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:20–16:00</td>
<td>EVLP and reconditioning – TBD</td>
<td>Bridge with EC devices – D. van Raemdonck</td>
</tr>
<tr>
<td>16:00–16:40</td>
<td>Bridge with EC devices – D. van Raemdonck</td>
<td>NHBD management – A. Neyrinck</td>
</tr>
<tr>
<td>16:40–17:20</td>
<td>NHBD management – A. Neyrinck</td>
<td>EVLP and reconditioning – TBD</td>
</tr>
</tbody>
</table>

17:30  Welcome cocktail

Friday, 20 November 2020

Session 4 – Early clinical care of the lung transplant recipient
Chair: TBD
08:30–09:00  PGD physiopathology and prevention – I. Inci
09:00–09:30  Primary graft dysfunction clinical management – A. Neyrinck
09:30–10:00  Acute cellular rejection and humoral rejection – F. Meloni
10:00–10:30  Pathological diagnosis of early complications (PGD, acute cellular and humoral rejection) – F. Calabrese
10:30–11:00  Airway complication after lung transplantation – G. Massard
11:00–11:30  Coffee Break

Interactive workshops 2: Case examples and discussion

<table>
<thead>
<tr>
<th>Time</th>
<th>Basic programme</th>
<th>Advanced programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15–13:00</td>
<td>Challenging pathological series – F. Calabrese</td>
<td>PGD – A. Olland</td>
</tr>
</tbody>
</table>

13:00–14:00  Lunch

Session 5– Immunosuppression
Chair: TBD
14:00–14:30  What’s new in induction therapy – TBD
14:30–15:00  Standard IS regimens: CNI is still the cornerstone – R. Vos
15:00–15:30  Alternative immunosuppressive strategies – J. Gottlieb
15:30–16:00  Coffee Break
Session 6 – Infections and the lung transplant candidate and recipient
Chairs: TBD
16:00–16:30 Prevention and treatment of viral infections: CMV and other community respiratory viruses – M. Perch
16:30–17:00 Aspergillus and other fungi – M. Perch
17:00–17:30 Bacterial infections – A. Holm
17:30–18:00 Complications in paediatric lung transplantation – TBD

Saturday, 21 November 2020

Session 7 – Chronic lung allograft dysfunction
Chairs: R. Vos
08:30–09:00 CLAD definition and CLAD phenotypes, definition and pathogenesis – G. Verleden
09:00–09:30 Immunoregulatory treatment: Strategies in BOS and RAS – F. Meloni
09:30–10:00 Treatment of risk factors – J. Gottlieb
10:00–10:20 Retransplantation for CLAD: indications, outcomes and ethical issues – G. Massard
10:20–10:50 Coffee Break

Session 8 – Long term complications after lung transplantation
Chairs: A. Holm
10:50–11:20 Renal dysfunction and cardiovascular disorders – F. Meloni
11:20–11:50 Lymphoproliferative disease and other malignancies – M. Perch

Interactive session
Chairs: R. Vos, A. Olland
11:50–12:30 Participant case discussion
12:30–13:30 Lunch

Interactive workshops 3: Case examples and discussion

<table>
<thead>
<tr>
<th>Time</th>
<th>Basic programme</th>
<th>Advanced programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–14:00</td>
<td>CLAD – G. Verleden</td>
<td>Management of kidney failure – F. Meloni</td>
</tr>
<tr>
<td>14:00–14:30</td>
<td>RAS – R Vos</td>
<td>Lung carcinoma – A. Olland</td>
</tr>
<tr>
<td>14:30–15:00</td>
<td>Management of kidney failure – F. Meloni</td>
<td>CLAD – G. Verleden</td>
</tr>
<tr>
<td>Time</td>
<td>Basic programme</td>
<td>Advanced programme</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>PTLD diagnosis and management – F. Calabrese /M. Perch</td>
<td>RAS – R Vos</td>
</tr>
<tr>
<td>15:30–16:00</td>
<td>Lung carcinoma – A. Olland</td>
<td>PTLD diagnosis and management – F. Calabrese /M. Perch</td>
</tr>
<tr>
<td>16:00–16:30</td>
<td>Course evaluation and closing remarks</td>
<td></td>
</tr>
</tbody>
</table>